Incannex enters agreements to reduce up to 50.4% of Series A warrant shares

Incannex Healthcare Inc.

First ~$12.5M net proceeds from ATM to cancel up to 5,833,333 underlying shares (adjustable to 175M).
Warrant exercise requires stockholder approval at May 27, 2025 special meeting.
CEO Joel Latham cites commitment to advancing IHL-42X for obstructive sleep apnea.
Agreements signed on May 15, 2025; potential reduction of up to 50.4% of warrant shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.